Analysts Expect Paratek Pharmaceuticals Inc (PRTK) Will Announce Quarterly Sales of $2.28 Million

Analysts forecast that Paratek Pharmaceuticals Inc (NASDAQ:PRTK) will post sales of $2.28 million for the current quarter, Zacks reports. Eight analysts have provided estimates for Paratek Pharmaceuticals’ earnings, with the highest sales estimate coming in at $3.02 million and the lowest estimate coming in at $1.50 million. Paratek Pharmaceuticals reported sales of $40,000.00 in the same quarter last year, which would suggest a positive year over year growth rate of 5,600%. The firm is expected to report its next quarterly earnings report on Thursday, August 1st.

According to Zacks, analysts expect that Paratek Pharmaceuticals will report full year sales of $18.45 million for the current year, with estimates ranging from $10.03 million to $57.71 million. For the next financial year, analysts forecast that the firm will post sales of $54.01 million, with estimates ranging from $22.58 million to $131.17 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Paratek Pharmaceuticals.

Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its quarterly earnings data on Wednesday, May 8th. The specialty pharmaceutical company reported ($1.10) EPS for the quarter, topping analysts’ consensus estimates of ($1.19) by $0.09. Paratek Pharmaceuticals had a negative net margin of 656.41% and a negative return on equity of 149.09%. The firm had revenue of $1.60 million during the quarter, compared to analyst estimates of $0.89 million.

PRTK has been the subject of a number of recent analyst reports. Canaccord Genuity raised their price objective on shares of Paratek Pharmaceuticals from $14.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, January 16th. HC Wainwright reissued a “buy” rating on shares of Paratek Pharmaceuticals in a research note on Thursday, February 28th. Wedbush reissued an “outperform” rating on shares of Paratek Pharmaceuticals in a research note on Wednesday, March 6th. LADENBURG THALM/SH SH set a $18.00 target price on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, February 28th. Finally, Zacks Investment Research raised shares of Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 15th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $22.25.

Several hedge funds have recently added to or reduced their stakes in PRTK. BNP Paribas Arbitrage SA acquired a new stake in shares of Paratek Pharmaceuticals in the 1st quarter valued at $36,000. Hsbc Holdings PLC acquired a new stake in shares of Paratek Pharmaceuticals in the 4th quarter valued at $59,000. Annex Advisory Services LLC lifted its stake in shares of Paratek Pharmaceuticals by 15.3% in the 4th quarter. Annex Advisory Services LLC now owns 15,100 shares of the specialty pharmaceutical company’s stock valued at $77,000 after purchasing an additional 2,000 shares during the last quarter. Stifel Financial Corp acquired a new stake in shares of Paratek Pharmaceuticals in the 4th quarter valued at $90,000. Finally, Raymond James Financial Services Advisors Inc. lifted its stake in shares of Paratek Pharmaceuticals by 15.3% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 18,867 shares of the specialty pharmaceutical company’s stock valued at $101,000 after purchasing an additional 2,500 shares during the last quarter. 74.25% of the stock is owned by institutional investors and hedge funds.

Paratek Pharmaceuticals stock traded up $0.43 during midday trading on Friday, reaching $5.54. The stock had a trading volume of 390,413 shares, compared to its average volume of 293,970. Paratek Pharmaceuticals has a twelve month low of $4.50 and a twelve month high of $12.30. The company has a debt-to-equity ratio of 4.81, a quick ratio of 14.41 and a current ratio of 14.41. The firm has a market capitalization of $166.94 million, a price-to-earnings ratio of -1.55 and a beta of 1.52.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.

Further Reading: What is a Lock-Up Period?

Get a free copy of the Zacks research report on Paratek Pharmaceuticals (PRTK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.